Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Times, WSJ and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 110d ago.
Quick answers
Why is "Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (3)
- Eli Lilly buys psychedelic drugs company AtaiBeckley for $3.8bn The Times · 123d ago
- Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion WSJ · 123d ago
- Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market Fierce Biotech · 123d ago
Topics
Related trends
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
Major drugmakers Novo Nordisk and Eli Lilly face numerous lawsuits alleging popular GLP-1 medications cause sudden vision loss.
Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly CFO On Acquisition Spree: 'We Are Taking Bets' On Future Revenue
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly stock reaches an all-time high amid surging GLP-1 sales and a heightened price target.
Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.